Barclays PLC Has $258,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB)

Barclays PLC cut its holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 30.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 120,497 shares of the biopharmaceutical company’s stock after selling 51,700 shares during the period. Barclays PLC owned approximately 0.30% of Cellectar Biosciences worth $258,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Oppenheimer & Co. Inc. bought a new stake in Cellectar Biosciences during the third quarter worth about $27,000. Rosalind Advisors Inc. lifted its position in Cellectar Biosciences by 35.7% during the third quarter. Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock worth $7,857,000 after purchasing an additional 965,934 shares during the period. Sequoia Financial Advisors LLC bought a new stake in Cellectar Biosciences during the third quarter worth about $51,000. XTX Topco Ltd lifted its position in Cellectar Biosciences by 432.4% during the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 51,413 shares during the period. Finally, AIGH Capital Management LLC lifted its position in Cellectar Biosciences by 8.2% during the second quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock worth $7,590,000 after purchasing an additional 231,270 shares during the period. Institutional investors own 16.41% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on CLRB. Oppenheimer reissued a “market perform” rating on shares of Cellectar Biosciences in a report on Wednesday, December 11th. LADENBURG THALM/SH SH began coverage on shares of Cellectar Biosciences in a report on Thursday, December 5th. They issued a “buy” rating and a $13.00 target price for the company. Finally, StockNews.com began coverage on shares of Cellectar Biosciences in a report on Sunday. They issued a “sell” rating for the company.

Cellectar Biosciences Price Performance

Cellectar Biosciences stock opened at $0.35 on Monday. The business has a 50 day moving average of $1.23 and a 200-day moving average of $1.88. Cellectar Biosciences, Inc. has a 1 year low of $0.22 and a 1 year high of $4.45. The company has a market capitalization of $14.25 million, a P/E ratio of -0.20 and a beta of 1.04.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. Equities analysts anticipate that Cellectar Biosciences, Inc. will post -1.59 EPS for the current year.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.